Drug Profile
Research programme: insulin oral - Abeona Therapeutics
Alternative Names: cobalamin-coated insulin-containing nanoparticles; CobOral™ InsulinLatest Information Update: 21 Jan 2022
Price :
$50
*
At a glance
- Originator Access Pharmaceuticals
- Developer Abeona Therapeutics
- Class Antihyperglycaemics; Hepatoprotectants; Insulins; Pancreatic hormones
- Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Tyrosine aminotransferase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Diabetes mellitus
Most Recent Events
- 24 May 2018 Discontinued - Preclinical for Diabetes mellitus in USA (PO)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Diabetes-mellitus in USA (PO)
- 10 Feb 2014 This programme is still in preclinical development in USA